ACCRETION PHARMA LIMITED Stock Price Today (NSE: ACCPL)
Fundamental Score
ACCRETION PHARMA LIMITED Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ACCRETION PHARMA LIMITED share price today is ₹148.05, up +7.20% on NSE/BSE as of 17 June 2026. ACCRETION PHARMA LIMITED (ACCPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹103.05 (Cr). The 52-week high for ACCPL share price is ₹133.85 and the 52-week low is ₹53.80. At a P/E ratio of 11.35x, ACCPL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 65.35% and a debt-to-equity ratio of 0.17.
ACCRETION PHARMA LIMITED Share Price Chart — NSE/BSE Historical Performance
ACCRETION PHARMA LIMITED share price chart: 25.08% return over the past month. 52-week high ₹133.85, 52-week low ₹53.80.
ACCRETION PHARMA LIMITED — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹129.00 | ₹133.85 | ₹127.00 | ₹133.65 | 63.60K (Cr) | |
| ₹118.00 | ₹118.00 | ₹116.00 | ₹117.45 | 16.80K (Cr) | |
| ₹115.00 | ₹115.00 | ₹108.95 | ₹108.95 | 19.20K (Cr) | |
| ₹122.95 | ₹122.95 | ₹114.65 | ₹114.65 | 7.20K (Cr) | |
| ₹119.20 | ₹127.00 | ₹118.00 | ₹126.80 | 42.00K (Cr) | |
| ₹111.90 | ₹123.60 | ₹111.90 | ₹122.65 | 1.43L (Cr) | |
| ₹111.40 | ₹114.85 | ₹107.00 | ₹108.00 | 34.80K (Cr) | |
| ₹114.05 | ₹114.05 | ₹108.35 | ₹109.40 | 82.80K (Cr) | |
| ₹100.65 | ₹103.50 | ₹98.60 | ₹103.50 | 1.31L (Cr) | |
| ₹94.45 | ₹94.45 | ₹91.00 | ₹93.90 | 14.40K (Cr) |
ACCRETION PHARMA LIMITED — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹129.00 | ₹133.85 | ₹127.00 | ₹133.65 | +3.60% | |
| ₹114.05 | ₹127.00 | ₹107.00 | ₹117.45 | +2.98% | |
| ₹69.70 | ₹103.50 | ₹65.70 | ₹103.50 | +48.49% | |
| ₹63.00 | ₹68.00 | ₹62.00 | ₹63.55 | +0.87% | |
| ₹66.05 | ₹73.20 | ₹66.05 | ₹68.50 | +3.71% | |
| ₹84.00 | ₹86.70 | ₹67.00 | ₹67.40 | -19.76% | |
| ₹88.10 | ₹102.00 | ₹83.70 | ₹88.00 | -0.11% | |
| ₹58.25 | ₹84.50 | ₹55.15 | ₹81.15 | +39.31% | |
| ₹58.25 | ₹58.95 | ₹53.80 | ₹56.75 | -2.58% | |
| ₹64.00 | ₹65.90 | ₹60.00 | ₹60.00 | -6.25% |
AI Research Briefing
Powered by Gemini · 2026-04-22
High-growth micro-cap CDMO play; chase momentum, keep stops tight.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Accretion Pharma's stock price has seen significant movement recently, prompting the exchange to request information from the company to ensure investors have the latest relevant details. The company has also announced the non-applicability of certain SEBI regulations for the quarter ended March 31, 2026.
CORE STORY (THE REAL GAME)
Accretion Pharma is a micro-cap CDMO play attempting to scale through contract manufacturing and generic formulations. The market is likely pricing in continued growth in generic medicine demand and potential benefits from government initiatives to boost domestic pharma manufacturing.
- Recent price momentum
- Strong Qtr YoY growth
- Favorable macro environment for Indian pharma
- Significant new order wins
- Positive regulatory updates
- Successful expansion into new markets
- Micro-cap liquidity risk
- High geographic concentration in Gujarat
- Exchange seeking clarification
FII decreased holdings by 1.06%.
Indian pharma sector benefits from government policy push and innovation drive.
Free cash flow data unavailable.
Expect continued growth driven by generic demand and government support. Monitor regulatory developments and geographic diversification.
Primary Thesis Risk
Illiquidity and concentration risk can lead to a rapid value collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
ACCRETION PHARMA LIMITED Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ACCRETION PHARMA LIMITED Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ACCPL across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (65.35%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (46.36%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 11.35 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (93.09%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (135.67%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.60x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.52%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 1.16%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
ACCRETION PHARMA LIMITED vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare ACCRETION PHARMA LIMITED with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
51.3/100 | ₹148.05₹148 | ₹103.05₹103.05 | 11.35Average 11.3 Average | 65.35%Excellent 65.35% Excellent | 46.36%Excellent 46.36% Excellent | 0.17Excellent 0.2 Excellent | — — | — — | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
ACCRETION PHARMA LIMITED Quarterly Performance
Latest quarterly metrics for ACCPL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
135.67%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
93.09%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
ACCRETION PHARMA LIMITED Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ACCPL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
ACCRETION PHARMA LIMITED Financial Statements
Annual income statement, balance sheet and cash flow for ACCRETION PHARMA LIMITED (ACCPL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for ACCRETION PHARMA LIMITED
About ACCPL (ACCRETION PHARMA LIMITED)
ACCRETION PHARMA LIMITED (ACCPL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a ...current market capitalisation of ₹103.05 (Cr). ACCRETION PHARMA LIMITED has delivered a Return on Equity (ROE) of 65.35% and a ROCE of 46.36%. The debt-to-equity ratio stands at 0.17, reflecting the company's capital structure. Investors tracking ACCPL share price can monitor key metrics including P/E ratio, promoter holding of 73.52%, and quarterly earnings growth.
Company Details
ACCPL Share Price: Frequently Asked Questions
What is the current share price of ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED (ACCPL) trades at ₹148.05 on NSE. Market cap ₹103.05 (Cr). Educational data only.
What is the P/E ratio of ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED has a P/E of 11.35x vs industry average 31.77x.
What is the Bull Run score for ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED has a Bull Run score of 51.3/100 based on 25+ financial parameters.
Does ACCRETION PHARMA LIMITED pay dividends?
ACCRETION PHARMA LIMITED has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED has ROE of 65.35%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of ACCRETION PHARMA LIMITED?
ACCRETION PHARMA LIMITED has debt-to-equity of 0.17.
Is ACCRETION PHARMA LIMITED a good investment?
Bull Run gives ACCRETION PHARMA LIMITED a score of 51.3/100. This is not investment advice — consult a SEBI-registered advisor.